Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics

Biochemical Pharmacology

Volumn 58, Issue 6, 1999, Pages 917-923

  Decker, Michael W ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 594; Analgesia; Epibatidine; nicotine; Nicotinic acetylcholine receptor; Pain

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (6 CHLORO 3 PYRIDAZINYL) 3,8 DIAZABICYCLO[3.2.1]OCTANE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; EPIBATIDINE; MECAMYLAMINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NEUROTRANSMITTER; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; OPIATE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL MODEL; BRAIN NUCLEUS; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; SPINAL CORD;

ANALGESICS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; NEURONS; NICOTINIC AGONISTS; PAIN; PYRIDINES; RECEPTORS, NICOTINIC;

EID: 0032807022     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00122-7     Document Type: Review

References (58)

1. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th Edn :1996;521-555 McGraw-Hill, New York.
2. Insel P.A. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th Edn :1996;617-657 McGraw-Hill, New York.
3. Ollat H., Cesaro P. Pharmacology of neuropathic pain. Clin Neuropharmacol. 18:1995;391-404.
4. Max M.B. Antidepressant drugs as treatments for chronic pain Efficacy and mechanisms . Bromm B., Desmedt J.E. Advances in Pain Research and Therapy. Vol. 22:1995;501-515 Raven Press, New York.
5. Dray A., Urban L., Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci. 15:1994;190-197.
6. Dray A., Urban L. New pharmacological strategies for pain relief. Annu Rev Pharmacol Toxicol. 36:1996;253-280.
7. Davis L., Pollock L.J., Stone T. Visceral pain. Surg Gynecol Obstet. 55:1932;418-426.
8. Sahley T.L., Berntson G.G. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacology. 65:1979;279-283.
9. Tripathi H.L., Martin B.R., Aceto M.D. Nicotine-induced antinociception in rats and mice Correlation with nicotine brain levels . J Pharmacol Exp Ther. 221:1982;91-96.
10. Aceto M.D., Awaya H., Martin B.R., May E.L. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. Br J Pharmacol. 79:1983;869-876.
11. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol. 45:1994;563-569.
12. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishnan M., Williams M., Arneric S.P. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 271:1994;624-631.
13. Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Brioni J.D., Radek R.J., McKenna D.G., Campbell J.E., Arneric S.P., Decker M.W., Bannon A.W. (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med Chem Res. 4:1994;502-516.
14. Bannon A.W., Gunther K.L., Decker M.W. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol Biochem Behav. 51:1995;693-698.
15. Holladay M.W., Dart M.J., Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem. 40:1997;4169-4194.
16. Boyd R.T. The molecular biology of neuronal nicotinic acetylcholine receptors. Crit Rev Toxicol. 27:1997;299-318.
17. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 41:1992;31-37.
18. Chen D.N., Patrick J.W. The α-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the α7 subunit. J Biol Chem. 272:1997;24024-24029.
19. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization . J Pharmacol Exp Ther. 285:1998;777-786.
20. Decker M.W., Bannon A.W., Curzon P., Gunther K.L., Brioni J.D., Holladay M.W., Lin N.-H., Li Y., Daanen J.F., Buccafusco J.J., Prendergast M.A., Jackson W.J., Arneric S.P. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride] II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys . J Pharmacol Exp Ther. 283:1997;247-258.
21. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raskiewickz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Williams M., Arneric S.P. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418) A novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. In vivo characterization . J Pharmacol Exp Ther. 270:1994;319-328.
22. Lin N.-H., Gunn D.E., Ryther K.B., Garvey D.S., Donnelly-Roberts D.L., Decker M.W., Brioni J.D., Buckley M.J., Rodrigues A.D., Marsh K.G., Anderson D.J., Buccafusco J.J., Prendergast M.A., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Structure-activity studies on 2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine (ABT-089) An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor (nAChR) ligand with cognition enhancing properties . J Med Chem. 40:1997;385-390.
23. Meyer E.M., Tay E.T., Papke R.L., Meyers C., Huang G.L., de Fiebre C.M. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 768:1997;49-56.
24. Briggs C.A., Anderson D.J., Brioni J.D., Buccafusco J.J., Buckley M.J., Campbell J.E., Decker M.W., Donnelly-Roberts D., Elliott R.L., Gopalakrishnan M., Holladay M.W., Hui Y.H., Jackson W.J., Kim D.J.B., Marsh K.C., O'Neill A., Prendergast M.A., Ryther K.B., Sullivan J.P., Arneric S.P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav. 57:1997;231-241.
25. Lloyd G.K., Menzaghi F., Bontempi B., Suto C., Siegel R., Akong M., Stauderman K., Velicelebi G., Johnson E., Harpold M.M., Rao T.S., Sacaan A.I., Chavez-Noriega L.E., Washburn M.S., Vernier J.M., Cosford N.D.P., McDonald L.A. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1998;1601-1606.
26. Bencherif M., Lovette M.E., Fowler K.W., Arrington S., Reeves L., Caldwell W.S., Lippiello P.M. RJR-2403 A nicotinic agonist with CNS selectivity I. In vitro characterization . J Pharmacol Exp Ther. 279:1996;1413-1421.
27. Lippiello P.M., Bencherif M., Gray J.A., Peters S., Grigoryan G., Hodges H., Collins A.C. RJR-2403 A nicotinic agonist with CNS selectivity II. In vivo characterization . J Pharmacol Exp Ther. 279:1996;1422-1429.
28. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Xue I.C., Piattoni-Kaplan M., Molinari E., Campbell J.E., McKenna D.G., Gunn D.E., Lin N.-H., Ryther K.B., He Y., Holladay M.W., Wonnacott S., Williams M., Arneric S.P. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]. I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther. 283:1997;235-246.
29. Barlocco D., Cignarella G., Tondi D., Vianello P., Villa S., Bartolini A., Ghelardini C., Galeotti N., Anderson D.J., Kuntzweiler T.A., Colombo D., Toma L. Mono- and disubstituted-3,8-diazabicyclo[3,2.1]octane derivatives as analgesics structurally related to epibatidine Synthesis, activity, and modeling . J Med Chem. 41:1998;674-681.
30. Ghelardini C., Galeotti N., Barlocco D., Bartolini A. Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Dev Res. 40:1997;251-258.
31. Holladay M.W., Wasicak J.T., Lin N.H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J.B., Decker M.W., Anderson D.J., Campbell J.E., Kuntzweiler T.A., Donnelly-Roberts D.L., Piattoni-Kaplan M., Briggs C.A., Williams M., Arneric S.P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J Med Chem. 41:1998;407-412.
32. Abreo M.A., Lin N.H., Garvey D.S., Gunn D.E., Hettinger A.M., Wasicak J.T., Pavlik P.A., Martin Y.C., Donnelly-Roberts D.L., Anderson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem. 39:1996;817-825.
33. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Piattoni-Kaplan M., Campbell J.E., McKenna D.G., Molinari E., Hettinger A.-M., Garvey D.S., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine] In vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand . Neuropharmacology. 35:1996;725-734.
34. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 279:1998;77-81.
35. Curzon P., Nikkel A.L., Bannon A.W., Arneric S.P., Decker M.W. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (±)-epibatidine in rats. J Pharmacol Exp Ther. 287:1998;847-853.
36. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J.B., Radek R.J., Lynch J.K., Wasicak J.T., Lin N.-H., Arnold W.H., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] A novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization . J Pharmacol Exp Ther. 285:1998;787-794.
37. Bannon A.W., Decker M.W., Kim D.J.B., Campbell J.E., Arneric S.P. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. 801:1998;158-163.
38. Decker M.W., Bannon A.W., Buckley M.J., Kim D.J.B., Holladay M.W., Ryther K.B., Lin N.-H., Wasicak J.T., Williams M., Arneric S.P. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur J Pharmacol. 346:1998;23-33.
39. Dussor G.O., Leong A.S., Gracia N.B., Hargreaves K.M., Arneric S.P., Flores C.M. Differential effects of neuronal nicotinic receptor agonists on capsaicin-evoked CGRP release from peripheral terminals of primary sensory neurons. Soc Neurosci Abstr. 24:1998;1625.
40. Decker M.W., Curzon P., Holladay M.W., Nikkel A.L., Bitner R.S., Bannon A.W., Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Williams M., Arneric S.P. The role of neuronal nicotinic acetylcholine receptors in antinociception Effects of ABT-594 . J Physiol (Paris). 92:1998;221-224.
41. Iwamoto E.T. Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther. 257:1991;120-133.
42. Mitchell S.N. Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology. 32:1993;937-949.
43. Wurtman R.J., Wurtman J.J. Brain serotonin, carbohydrate-craving, obesity and depression. Adv Exp Med Biol. 398:1996;35-41.
44. 3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem. 59:1992;848-856.
45. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.
46. Rogers D.T., Iwamoto E.T. Multiple spinal mediators in parenteral nicotine-induced antinociception. J Pharmacol Exp Ther. 267:1993;341-349.
47. Iwamoto E.T., Marion L. Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther. 265:1993;777-789.
48. Iwamoto E.T. Antinociception after nicotine administration into the mesopontine tegmentum of rats Evidence for muscarinic actions . J Pharmacol Exp Ther. 251:1989;412-421.
49. Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W. Role of the nucleus raphe magnus in antinociception produced by ABT-594 Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons . J Neurosci. 18:1998;5426-5432.
50. Damaj M.I., Fei-Yin M., Dukat M., Glassco W., Glennon R.A., Martin B.R. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther. 284:1998;1058-1065.
51. Khan I.M., Yaksh T.L., Taylor P. Epibatidine binding sites and activity in the spinal cord. Brain Res. 753:1997;269-282.
52. Hamann S.R., Martin W.R. Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. J Pharmacol Exp Ther. 261:1992;707-715.
53. Slade J., Henningfield J.E. Tobacco product regulation Context and issues . Food Drug Law J. 53:1998;43-74.
54. Fudala P.J., Iwamoto E.T. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol Biochem Behav. 25:1986;1041-1049.
55. Shoaib M., Stolerman I.P., Kumar R.C. Nicotine-induced place preferences following prior nicotine exposure in rats. Psychopharmacology. 113:1994;445-452.
56. Rose J.E., Corrigall W.A. Nicotine self-administration in animals and humans Similarities and differences . Psychopharmacology. 130:1997;28-40.
57. Pomerleau O.F. Nicotine as a psychoactive drug Anxiety and pain reduction . Psychopharm Bull. 22:1986;865-869.
58. Perkins K.A., Grobe J.E., Stiller R.L., Scierka A., Goettler J., Reynolds W., Jennings J.R. Effects of nicotine on thermal pain detection in humans. Exp Clin Psychopharmacol. 2:1994;95-106.